Related Experiment Video
Updated: May 16, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
The Prevalence of Insomnia Disorder in the General Population: A Meta-Analysis
Annemieke van Straten1,2, Karl Juri Weinreich1,3, Bernát Fábián1
1Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
None:
Insomnia disorder is a significant public health issue, but the prevalence estimates vary widely. We performed a meta-analysis aiming to pool prevalence rates in studies (1) carried out in the general population (2) using a true random sample (3) and using a diagnostic interview, DSM based self-report questions, or a questionnaire with a cut-off established against the DSM criteria. A literature search (in PubMed, Embase, APA PsycInfo) was performed up to April 2024. Two independent reviewers assessed title and abstracts (n = 6732), full-text manuscripts (n = 621) and extracted the data of the 47 included studies. Prevalence rates were pooled using a three-level hierarchical random-effects model, stratified by diagnosis type and adjusted for gender distribution and mean sample age. The pooled prevalence of all studies using an interview to establish the DSM criteria was 12.4% (95% CI: 9.0-16.8%), and of self-report questions assessing the DSM diagnosis 16.3% (95% CI: 11.3%-23.0%). There were 27 studies using different insomnia questionnaires with different cut-offs (prevalence range 7.5%-32.3%). The prevalences differed significantly across regions and high quality studies yielded a lower prevalence rates than lower quality studies. This meta-analysis confirms that insomnia is a common disorder with a prevalence of 12.4 as the most accurate estimate. It also shows the need for standardised ways of assessing insomnia. We think the golden standard is using standardised structured clinical interviews. However, if this is not feasible, we recommend using well validated questionnaires such as the Sleep Condition Indicator or the Insomnia Severity Index. Trial Registration: PROSPERO CRD42023402745.
More Related Videos
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
Related Concept Videos
Insomnia
Multiple factors contribute...
Management of Insomnia
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Generalized Anxiety Disorder
Diagnostic and Statistical Manual of Mental Disorders (DSM)